دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
The Medical Management of Paediatric Crohn’s Disease: an ECCO-ESPGHAN Guideline Update
Patrick F van Rheenen, Marina Aloi, Amit Assa, Jiri Bronsky, Johanna C Escher ...
doi : 10.1093/ecco-jcc/jjaa161
Volume 15, Issue 2, February 2021, Pages 171–194
We aimed to provide an evidence-supported update of the ECCO-ESPGHAN guideline on the medical management of paediatric Crohn’s disease [CD].
Early Intervention With Vedolizumab and Longer-term Surgery Rates in Crohn’s Disease: Post Hoc Analysis of the GEMINI Phase 3 and Long-term Safety Programmes
Parambir S Dulai, Laurent Peyrin-Biroulet, Dirk Demuth, Karen Lasch, Kristen A Hahn ...
doi : 10.1093/ecco-jcc/jjaa153
Volume 15, Issue 2, February 2021, Pages 195–202
Crohn’s disease [CD] is a chronic inflammatory bowel disease that, with progression, may require surgical intervention.
Prevalence and Duration of Gastrointestinal Symptoms Before Diagnosis of Inflammatory Bowel Disease and Predictors of Timely Specialist Review: A Population-Based Study
J Blackwell, S Saxena, N Jayasooriya, A Bottle, I Petersen ...
doi : 10.1093/ecco-jcc/jjaa146
Volume 15, Issue 2, February 2021, Pages 203–211
Lack of timely referral and significant waits for specialist review amongst individuals with unresolved gastrointestinal [GI] symptoms can result in delayed diagnosis of inflammatory bowel disease [IBD].
Microscopic Colitis and Risk Of Cancer—AA Population-Based Cohort Study
David Bergman, Hamed Khalili, Bjorn Roelstraete, Jonas F Ludvigsson
doi : 10.1093/ecco-jcc/jjaa156
Volume 15, Issue 2, February 2021, Pages 212–221
The association between microscopic colitis [MC] and cancer risk is unclear. Large, population-based studies are lacking.
Effectiveness and Safety of Ustekinumab Intensification at 90 mg Every 4 Weeks in Crohn’s Disease: A Multicentre Study
Mathurin Fumery, Laurent Peyrin-Biroulet, Stephane Nancey, Romain Altwegg, Cyrielle Gilletta ...
doi : 10.1093/ecco-jcc/jjaa177
Volume 15, Issue 2, February 2021, Pages 222–227
The approved maintenance regimens for ustekinumab in Crohn’s disease [CD] are 90 mg every 8 or 12 weeks. Some patients will respond partially to ustekinumab or will experience a secondary loss of response. It remains poorly known if these patients may benefit from shortening the interval between injections.
A Global, Prospective, Observational Study Measuring Disease Burden and Suffering in Patients With Ulcerative Colitis, Using the Pictorial Representation of Illness and Self-measure Tool
Subrata Ghosh, Tom Sensky, Francesc Casellas, Louis-Charles Rioux, Tariq Ahmad ...
doi : 10.1093/ecco-jcc/jjaa159
Volume 15, Issue 2, February 2021, Pages 228–237
The understanding the Impact of ulcerative COlitis aNd Its assoCiated disease burden on patients study [ICONIC] was a 2-year, global, prospective, observational study evaluating the cumulative burden of ulcerative colitis [UC] using the Pictorial Representation of Illness and Self-Measure [PRISM] tool that is validated to measure suffering, but has not previously been used in UC.
Clinical Predictors of Response to Faecal Microbiota Transplantation in Patients with Active Ulcerative Colitis
Ajit Sood, Arshdeep Singh, Ramit Mahajan, Vandana Midha, Kirandeep Kaur ...
doi : 10.1093/ecco-jcc/jjaa163
Volume 15, Issue 2, February 2021, Pages 238–243
Faecal microbiota transplantation [FMT] has been shown to be effective for induction of remission in patients with active ulcerative colitis [UC]. At present, the clinical factors impacting the response to FMT in UC remain unclear.
The JAK1/3 Inhibitor to Tofacitinib Suppresses T Cell Homing and Activation in Chronic Intestinal Inflammation
Katharina Gerlach, Kristina Lechner, Vanessa Popp, Laura Offensperger, Sebastian Zundler ...
doi : 10.1093/ecco-jcc/jjaa162
Volume 15, Issue 2, February 2021, Pages 244–257
The molecular mechanism of action of the Janus kinase [JAK] inhibitor tofacitinib is poorly understood.
Gut Microbial Transcytosis Induced by Tumour Necrosis Factor-like 1A-dependent Activation of a Myosin Light Chain Kinase Splice Variant Contributes to Inflammatory Bowel Disease
Yu-Chen Pai, Li-Ting Weng, Shu-Chen Wei, Li-Ling Wu, David Q Shih ...
doi : 10.1093/ecco-jcc/jjaa165
Volume 15, Issue 2, February 2021, Pages 258–272
Inflammatory bowel disease [IBD] is characterised by abnormal host-microbe interactions. Proinflammatory cytokine IFN? and a novel tumour necrosis factor [TNF] superfamily member, TL1A, have been implicated in epithelial barrier dysfunction. The divergent regulatory mechanisms of transcellular versus paracellular hyperpermeability remain poorly understood.
Mucosal Inflammatory and Wound Healing Gene Programmes Reveal Targets for Stricturing Behaviour in Paediatric Crohn’s Disease
Yael Haberman, Phillip Minar, Rebekah Karns, Phillip J Dexheimer, Sudhir Ghandikota ...
doi : 10.1093/ecco-jcc/jjaa166
Volume 15, Issue 2, February 2021, Pages 273–286
Ileal strictures are the major indication for resective surgery in Crohn’s disease [CD]. We aimed to define ileal gene programmes present at diagnosis and linked with future stricturing behaviour during 5-year follow-up, and to identify potential small molecules to reverse these gene signatures.
Solute Carrier Family 12 Member 2 as a Proteomic and Histological Biomarker of Dysplasia and Neoplasia in Ulcerative Colitis
Angela-Maria Merli, Sophie Vieujean, Charlotte Massot, Noella Blétard, Florence Quesada Calvo ...
doi : 10.1093/ecco-jcc/jjaa168
Volume 15, Issue 2, February 2021, Pages 287–298
Ulcerative colitis [UC] patients have a greater risk of developing colorectal cancer through inflammation-dysplasia-carcinoma sequence of transformation. The histopathological diagnosis of dysplasia is therefore of critical clinical relevance, but dysplasia may be difficult to distinguish from inflammatory changes.
The Impact of Rectal Stump Inflammation After Subtotal Colectomy on Pouch Outcomes in Ulcerative Colitis Patients
Karin A Wasmann, Eline M van der Does de Willebois, Lianne Koens, Marjolijn Duijvestein, Willem A Bemelman ...
doi : 10.1093/ecco-jcc/jjaa157
Volume 15, Issue 2, February 2021, Pages 299–306
Proctitis after subtotal colectomy with ileostomy for ulcerative colitis [UC] is common, but its impact on short- and long-term outcome after pouch surgery is unknown. The aim of this study was to determine the incidence of proctitis after subtotal colectomy and its impact on postoperative morbidity and pouchitis.
Gut Microbiota-driven Drug Metabolism in Inflammatory Bowel Disease
Femke Crouwel, Hans J C Buiter, Nanne K de Boer
doi : 10.1093/ecco-jcc/jjaa143
Volume 15, Issue 2, February 2021, Pages 307–315
The gut microbiota plays an important role in the metabolization and modulation of several types of drugs. With this study we aimed to review the literature relating to microbial drug metabolism of medication prescribed in inflammatory bowel disease [IBD] practice.
Varicella Zoster Virus in Inflammatory Bowel Disease Patients: What Every Gastroenterologist Should Know
Philipp Schreiner, Nicolas J Mueller, Jan Fehr, Michel H Maillard, Stephan Brand ...
doi : 10.1093/ecco-jcc/jjaa132
Volume 15, Issue 2, February 2021, Pages 316–325
Primary varicella zoster virus [VZV] infection results in varicella [chickenpox] and its reactivation results in herpes zoster [HZ; shingles]. Patients with inflammatory bowel disease [IBD] are susceptible to complications of primary VZV infection and have an increased risk of HZ.
Are Quality Metrics in Inflammatory Bowel Disease Rooted in Substantial Quality Evidence? A Systematic Review
Simcha Weissman, Alexander Goldowsky, Tej I Mehta, Michael A Sciarra, Joseph D Feuerstein
doi : 10.1093/ecco-jcc/jjaa123
Volume 15, Issue 2, February 2021, Pages 326–334
Quality metrics were established to develop standards to help assess quality of care, yet variation in inflammatory bowel disease [IBD] clinical practice exists. We performed a systematic review to assess the overall quality of evidence cited in formulating IBD quality metrics.
Dual Targeted Therapy: A Possible Option for the Management of Refractory Inflammatory Bowel Disease
Giuseppe Privitera, Sara Onali, Daniela Pugliese, Sara Renna, Edoardo Savarino ...
doi : 10.1093/ecco-jcc/jjaa149
Volume 15, Issue 2, February 2021, Pages 335–339
Dual targeted therapy [DTT] has been proposed as a novel therapeutic strategy for the management of complicated patients with inflammatory bowel diseases [IBD]. Our aim here was to investigate the safety and effectiveness of this approach in a real-life setting.
Segmental Colectomy: An Alternative for Ulcerative Colitis in Endoscopic Remission?
Rogério Serafim Parra, Marley Ribeiro Feitosa, Omar Féres
doi : 10.1093/ecco-jcc/jjaa141
Volume 15, Issue 2, February 2021, Page 340
Frontali et al.1 recently published a retrospective multicentric experience of segmental colectomy [SC] in 72 patients diagnosed with ulcerative colitis [UC] and in endoscopic remission. After SC, postoperative early colitis was rare [7.0%], suggesting that SC could be a surgical alternative for UC patients in endoscopic remission.
Patient Involvement in IBD Service Standards and Quality Improvement
A Barney Hawthorne, Rukshana Kapasi, Ian Arnott
doi : 10.1093/ecco-jcc/jjaa142
Volume 15, Issue 2, February 2021, Page 341
We read with interest the review of quality metrics in inflammatory bowel disease [IBD] by Weissman and colleagues.1 We agree that many service quality standards are not supported by high-quality evidence and there is a huge range of measures, many of which are not easily quantified. IBD is a complex chronic condition, with care delivered to patients over many years by multidisciplinary teams, and IBD services vary enormously in size and structure. This makes measurement of service quality challenging.
Diagnostic Delay due to Anti-tubercular Therapy in Crohn’s Disease: A Red Herring?
Venigalla Pratap Mouli, Akshita Gupta, Vineet Ahuja
doi : 10.1093/ecco-jcc/jjaa155
Volume 15, Issue 2, February 2021, Page 342
We thank Dai et al.1 for their interest in our research work.2 We agree with the author that diagnostic and hence treatment delay in patients with Crohn’s disease [CD] would accelerate the disease progression, causing a complicated disease course manifested by higher frequency of stricture formation and increased rates of surgery.3 However, we did consider this fact during our analysis, and after propensity matching, the diagnostic delay [from symptom onset till diagnosis of CD]was similar in the group which received???6 months of anti-tubercular therapy [ATT] versus the one which did not (24 [6–180] vs 24 [1–360] months, p...
Interpretations of Trends in Incidence of Microscopic Colitis
Lars Kristian Munck
doi : 10.1093/ecco-jcc/jjaa224
Volume 15, Issue 2, February 2021, Page 343
The paper by Weimers et al1 confirms the previously published high incidence of microscopic colitis in Denmark and that the incidence has recently levelled off.2 The incidence was approximately 23–28 per 100 000 inhabitants per year in the region of Zealand from 2011 through 2016.2 An error in the legend to Figure 41 impedes the interpretation of regional differences between the Danish regions. Nevertheless, the interpretation of these results needs a more thorough discussion. The Zealand region is comparable to the North Denmark region, but the incidence was much lower despite a high degree of awareness. It is difficult to...
Authors’ Response: Interpretations of Trends in Incidence of Microscopic Colitis
Petra Weimers, Dorit Vedel Ankersen, Ole K Bonderup, Ellen Christine Leth L?kkegaard, Johan Burisch ...
doi : 10.1093/ecco-jcc/jjaa262
Volume 15, Issue 2, February 2021, Page 344
We would like to thank Dr Munck1 for his interest and comments on our paper, ‘Incidence and prevalence of microscopic colitis between 2001 and 2016: A Danish nationwide cohort study’.2 Microscopic colitis [MC] was initially considered to be a rare disease, but has now emerged to be a common cause of non-bloody watery diarrhoea.3 In the letter, Dr Munck suggests that the increasing incidence of MC as well as the differences in incidence between regions of Denmark might be caused by increased use of newer histological stains as well as increased disease awareness among physicians. Moreover, Dr Munck also highlights the...
Erratum to: Efficacy of Granulocyte and Monocyte Adsorptive Apheresis in Patients With Inflammatory Bowel Disease Showing Lost Response to Infliximab
Yoko Yokoyama, Koji Sawada, Nobuo Aoyama, Naoki Yoshimura, Minako Sako ...
doi : 10.1093/ecco-jcc/jjaa211
Volume 15, Issue 2, February 2021, Page 345
No Abstract
